Document Detail


Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid.
MedLine Citation:
PMID:  20484933     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite advances in the treatment of vasculitis, modern therapies fail to induce or maintain remission in a significant proportion of patients. Mycophenolic acid is increasingly used to treat vasculitis syndromes. Here, we consider relevant pharmacokinetic and pharmacodynamic properties of mycophenolate, with emphasis on the impact of renal impairment, and we review the existing evidence for and current trials of mycophenolate in the treatment of primary systemic vasculitides.
Authors:
Thomas F Hiemstra; Rachel B Jones; David R W Jayne
Related Documents :
19783713 - Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is dif...
23830453 - In situ extractive fermentation for the production of hexanoic acid from galactitol by ...
11093583 - The study of nonspecific internalization of cholesteryl esters by the hep g2 hepatoma c...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-05-12
Journal Detail:
Title:  Nephron. Clinical practice     Volume:  116     ISSN:  1660-2110     ISO Abbreviation:  Nephron Clin Pract     Publication Date:  2010  
Date Detail:
Created Date:  2010-08-24     Completed Date:  2011-05-31     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101159763     Medline TA:  Nephron Clin Pract     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  c1-10     Citation Subset:  IM    
Affiliation:
Lupus and Vasculitis Unit, Addenbrookes Hospital, Cambridge, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Enzyme Inhibitors / pharmacokinetics,  pharmacology,  therapeutic use*
Humans
IMP Dehydrogenase / antagonists & inhibitors*,  physiology
Mycophenolic Acid / analogs & derivatives,  pharmacokinetics,  pharmacology,  therapeutic use*
Prodrugs / pharmacokinetics,  pharmacology,  therapeutic use
Randomized Controlled Trials as Topic / methods
Signal Transduction / drug effects,  physiology
Systemic Vasculitis / drug therapy*,  enzymology*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Prodrugs; 24280-93-1/Mycophenolic Acid; 9242ECW6R0/mycophenolate mofetil; EC 1.1.1.205/IMP Dehydrogenase; EC 1.1.1.205/IMPDH1 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TAS2R38 Genotypes and Phenylthiocarbamide Bitter Taste Perception in a Population of Young Adults.
Next Document:  Therapeutic remedies based on Aristolochia clematitis in the main foci of balkan endemic nephropathy...